BioNexus Gene Lab (BGLC) Invested Capital (2018 - 2026)

BioNexus Gene Lab (BGLC) posted Invested Capital of $54375.0 for Q1 2026, up 59.7% sequentially from $34049.0 in Q1 2022.

BioNexus Gene Lab (BGLC) Invested Capital (2018 - 2026) Analysis & Trends

BioNexus Gene Lab has reported Invested Capital for 6 years, with the latest figure at $54375.0 in Q1 2026.

Quarterly Invested Capital changed N/A year-over-year to $54375.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $54375.0 (changed N/A YoY) and the FY2021 annual result came in at $34038.0, down 43.59% from the prior year.
Invested Capital grew to $54375.0 in Q1 2026 per BGLC's latest filing, from $34049.0 in the prior quarter.
Over five years, Invested Capital peaked at $54375.0 in Q1 2026 and troughed at $34049.0 in Q1 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Invested Cap. (Qtr)
1	Linde	225.67 Bn	220.77 Bn	4.43 Bn	4.86 Bn
2	Sherwin Williams	84.74 Bn	84.44 Bn	3.34 Bn	2.25 Bn
3	Ecolab	78.90 Bn	73.77 Bn	1.95 Bn	13.17 Bn
4	Air Products & Chemicals	68.19 Bn	67.21 Bn	1.04 Bn	215.70 Mn
5	Ppg Industries	25.36 Bn	23.77 Bn	1.81 Bn	691.00 Mn
6	Chemical & Mining Co Of Chile	23.48 Bn	19.61 Bn	778.60 Mn	-
7	LyondellBasell Industries	21.91 Bn	19.28 Bn	2.04 Bn	1.46 Bn
8	International Flavors & Fragrances	21.51 Bn	20.94 Bn	853.00 Mn	964.00 Mn
9	DuPont de Nemours	18.83 Bn	17.09 Bn	639.00 Mn	-
10	BioNexus Gene Lab	2.28 Mn	-1.25 Mn	12,982.00	52,558.00

Download Data